Psoriasis drug bimekizumab: new study looks at gene changes
NCT ID NCT06506916
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects the body at a molecular level, not to cure the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bimekizumab (a biologic drug given as an injection)
What this could lead to
If successful, this study could show how bimekizumab works at the genetic level, potentially leading to better treatments for psoriasis and psoriatic arthritis.
What could go wrong
This is an exploratory study focused on gene markers, not on curing the disease. Results may not lead to new treatments, and side effects are possible with any biologic drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ps0039 40072
Freiburg im Breisgau, Germany
-
Ps0039 40287
Frankfurt am Main, Germany
-
Ps0039 40347
Lodz, Poland
-
Ps0039 40515
Berlin, Germany
-
Ps0039 40625
Warsaw, Poland
-
Ps0039 40757
Poznan, Poland
-
Ps0039 40761
Warsaw, Poland
-
Ps0039 40773
Wroclaw, Poland
-
Ps0039 50110
Ann Arbor, Michigan, 48109, United States
-
Ps0039 50140
Birmingham, Alabama, 35233, United States
-
Ps0039 50162
Fountain Valley, California, 92708, United States
-
Ps0039 50283
Tampa, Florida, 33613, United States
-
Ps0039 50491
Pittsburgh, Pennsylvania, 15213-2536, United States
-
Ps0039 50643
Rochester, New York, 14623, United States